SCHEMBL22554049

SCHEMBL22554049

O=C(NCc1nc2ccccc2o1)c1cc2c(-c3cncc(-c4ccc(N5CCCC5=O)cc4)c3)ccnc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.42
METTL14 Q9HCE5 1/20 0.42
ROCK2 O75116 1/20 0.42
DGAT2 Q96PD7 1/20 0.40
SYK P43405 1/20 0.39
NUDT1 P36639 2/20 0.38
TBK1 Q9UHD2 1/20 0.37
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
LMNA P02545 1/20 0.36
HPGDS O60760 1/20 0.35
NPC1 O15118 1/20 0.34
NAMPT P43490 1/20 0.34
AURKA O14965 2/20 0.34
AURKB Q96GD4 2/20 0.34
MAPT P10636 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22553982 0.88 DGAT2 (0.41) METTL3METTL14DGAT2NUDT1TBK1
SCHEMBL22553765 0.86 DGAT2 (0.41) METTL3METTL14ROCK2DGAT2NUDT1
SCHEMBL22554129 0.86 METTL3 (0.46) METTL3METTL14DGAT2NUDT1TBK1
SCHEMBL22554039 0.86 ROCK2 (0.43) METTL3METTL14ROCK2DGAT2SYK
SCHEMBL30730866 0.85 DGAT2 (0.43) METTL3METTL14ROCK2DGAT2NUDT1
SCHEMBL22554015 0.85 DGAT2 (0.43) METTL3METTL14ROCK2DGAT2NUDT1
SCHEMBL22553821 0.85 ROCK2 (0.42) METTL3METTL14ROCK2DGAT2NUDT1
SCHEMBL22553791 0.84 DGAT2 (0.41) METTL3METTL14DGAT2SYKNUDT1
SCHEMBL22554104 0.84 NUDT1 (0.47) METTL3METTL14DGAT2NUDT1TBK1
SCHEMBL30730856 0.84 NUDT1 (0.47) METTL3METTL14DGAT2NUDT1TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US claimed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C METTL3 2761/4885METTL14 2840/4885ROCK2 1231/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C METTL3 2761/4885METTL14 2840/4885ROCK2 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.